CFD:er är komplexa instrument som innebär hög risk att du förlorar pengar snabbt på grund av hävstången. 77,3% av icke-professionella investerares konton förlorar pengar när de handlar med CFD:er hos den här leverantören. Du bör överväga om du förstår hur CFD:er fungerar och om du har råd att ta den höga risken att förlora dina pengar.

Close

Affär BioNTech BNTX

Sälj
 Köp

BioNTech realtidsdiagram

5m 15m 30m 1h 4h 1d 1w

Instrumentfundament

Weekly Search
Weekly
Daily
Datum Stäng Förändring Förändring (%) Öppna Hög Låg

BioNTech news

Tommy Yap 2025 Mar 04, 16:00

Week Ahead: U.S. Inflation Data and BoC Policy Rate in Focus

Forex Indices
Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares
Pfizer shares sink as revenue prospects
Georgy Istigechev 2023 Dec 14, 05:13

Pfizer shares sink on lower COVID revenue prospects

Shares
shutterstock_1781525795.jpg
Zachariah Walker 2023 Feb 14, 09:11

5 Stocks to Fall in Love with this Valentines Day

2021 Aug 24, 08:05

Stocks make further gains as oil bounce carries on

Senaste nyheter

Visa mer
Frances Wang 2025 Maj 07, 16:00

Stock Market Today: Dow Jones Up, Nvidia stock fluctuates, Nasdaq Rises

Stocks Indices NVDA
Tommy Yap 2025 Maj 07, 16:00

Morning Note: BoE Rate Cut?, US Jobs, Toyota Earnings Today

Morning Note USD GBP
Frances Wang 2025 Maj 06, 16:00

Trending forex pairs: EUR/USD Fluctuates, USD/TWD Drops, AUD/JPY Rises

Forex
Tommy Yap 2025 Maj 06, 16:00

Morning Note: Fed Rate Decision Awaited; Uber's Report Looms; Oil Recovers Ground

Morning Note Fed Oil USD
Frances Wang 2025 Maj 05, 16:00

XRP news today: Ripple Launches First-of-Its-Kind $25M RLUSD Fund

Cryptocurrencies
Tommy Yap 2025 Maj 05, 16:00

Morning Note: Cautious Optimism on US-China Trade; AMD & Arista Reports Loom

Morning Note Tech
Tommy Yap 2025 Maj 04, 16:00

Morning Note: Palantir's Report in Focus; Stable Swiss CPI; US Services Data Due

Morning Note Tech
an alarm clock with an arrow going up and down
Tommy Yap 2025 Maj 03, 21:00

Week Ahead: Fed and BoE Interest Rate Announcements in the Spotlight

Forex Indices

Info

Spread

0.8266

Spread (%)

0.8951 %

Hävstångseffekt

1:5

Köp till dagslåneränta

-0.0597 %

Sälj till dagslåneränta

-0.0292 %

Valuta

USD

Handelstider

Marknaderna är stängda

Torsdag

13:31 - 19:59

Måndag

13:31-19:59

Tisdag

13:31-19:59

Onsdag

13:31-19:59

Fredag

13:31-19:59

Analys och statistik

Öppna

---

Föregående stängning

---

52 veckors högsta/lägsta

--- – ---

Marknadsvärde

25226842112

Utelöpande aktier

240392992

Rapportdatum (nästa)

0000-00-00

Utd-procent

2022-06-17

Datum efter utdelning

2022-06-02

Förväntad framtida årlig utdelningsprocent

0

Förväntad framtida årlig direktavkastning

0

Vinst per aktie

-3.14

Läs mer om detta instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Läs mer om detta instrument

Tillgång
Sälj
Köp
Förändring (%)

Handla nu

Handla nu

Handla nu

Handla nu
Relaterade instrument

latest_education_articles

Visa mer
Trustpilot